Загрузка...
Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine
In 2019, the United States Food and Drug Administration accorded restricted approval to Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito-borne viral disease, caused by four antigenically distinct dengue virus serotypes (DENV 1-4). The reason for this limi...
Сохранить в:
| Опубликовано в: : | Front Cell Infect Microbiol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7642463/ https://ncbi.nlm.nih.gov/pubmed/33194810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcimb.2020.572681 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|